JCR Pharmaceuticals Showcases Preclinical Gene Therapy Findings Demonstrating Strong CNS Uptake at the American Society of Gene and Cell Therapy 29th Annual Meeting JCR Pharmaceuticals presented new preclinical findings highlighting…
AeroRx Therapeutics Reports Positive Phase 2a Results for Inhaled AERO-007 in COPD as First Nebulized LABA/LAMA Combination Candidate AeroRx Therapeutics has reported positive Phase 2a clinical data for AERO-007, an…
Sumitomo Pharma America Presents AUA 2026 Data Showing Vibegron Benefits in Older Men With Overactive Bladder and BPH Sumitomo Pharma America presented new clinical and real-world evidence from its urology…
iECURE Reports Durable Response With ECUR-506 in OTC-HOPE Trial and Reduced Hyperammonemic Events in Initial Cohort iECURE has reported encouraging preliminary clinical data from the low-dose cohort of its ongoing…
TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board With Industry Experts TRIANA Biomedicines has announced a series of major leadership and scientific advisory appointments as the…
Orca Bio Names Bijan Nejadnik as Chief Medical Officer Orca Bio has announced a major leadership transition as the company continues advancing toward commercialization of its high-precision cell therapy platform.…
ImmunityBio Secures U.S. Patent Protection Through 2035 for ANKTIVA-BCG Combination Cancer Therapy ImmunityBio has announced the issuance of five United States patents covering the combination of its IL-15 receptor agonist…
Endospan Completes Acquisition by Artivion, Inc. After FDA Approval of the NEXUS® Aortic Arch System Endospan has announced the completion of its acquisition by Artivion in a deal that significantly…
Target RWE and NoviSci Rebrand as Pedestal Health and Headwater Science Target RWE and NoviSci have announced a major rebranding initiative as the two organizations position themselves to reshape how…
BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment…
Gossamer Bio Reports Q1 2026 Financial Results and Highlights Recent Business Progress Gossamer Bio has reported its financial results for the first quarter ended March 31, 2026, while also providing…
Parabilis Medicines Partners With Regeneron Pharmaceuticals to Develop Antibody-Helicon™ Conjugates Across Multiple Diseases Parabilis Medicines has entered into a major strategic research collaboration with Regeneron Pharmaceuticals aimed at advancing a…